THE PROOF, IN FULL

We measure every patient. Here's what the data shows.

Across 3,600+ patients, JLC records validated clinical scales at intake and throughout treatment. These are the average reductions from baseline: the same numbers we report to states, providers, and families.

VETERANS · FIRST RESPONDERS · LAW ENFORCEMENT

eTMS brain-health outcomes

Average symptom reductions among patients in our eTMS programs for those who serve.

PTSD symptoms
0 %
Anxiety
0 %
Depression
0 %
Sleep / insomnia
0 %
Bar chart of average symptom and craving decreases for eTMS patients: anxiety (GAD-7) 64.5%, PTSD (PCL-5) 63.0%, depression (BDI-II) 60.4%, insomnia (ISI) 59.7%, opioid cravings (OCS) 57.0%, alcohol cravings (PACS) 49.7%. Based on 3,728 total patients as of August 25, 2026.

Average symptom and craving reductions across measured JLC eTMS patients. Source: JLC SFI Dashboard, August 25, 2026.

OHIO ADDICTION PILOT

eTMS for Substance Use Disorder

Beginning March 2024 at Ohio addiction-treatment sites, JLC added eTMS to standard care for 177 patients, fentanyl the single largest group. Average change from baseline across all substances:

Opioid cravings
0 %

OCS · 156 patients

Stimulant cravings
0 %

BSC · 153 patients

Alcohol cravings
0 %

PACS · 150 patients

Depression
0 %

BDI-II · 156 patients

Anxiety
0 %

GAD-7 · 156 patients

Insomnia / sleep
0 %

ISI · 150 patients

PTSD symptoms
0 %

PCL-5 · 95 patients

Fentanyl patients specifically (n = 44)

Opioid cravings (OCS)
0 %

15.4 → 4.9 average score

Depression (BDI-II)
0 %

28.3 → 11.6 average score

Anxiety (GAD-7)
0 %

12.2 → 5.7 average score

Insomnia (ISI)
0 %

16.1 → 7.6 average score

PTSD (PCL-5)
0 %

43.6 → 20.3 average score

HOW WE MEASURE

Gold-standard scales, on every patient.

OCS (Opioid Craving) · PACS (Penn Alcohol Craving) · BSC (Brief Stimulant Craving) · PCL-5 (PTSD) · BDI-II / PHQ-9 (Depression) · GAD-7 (Anxiety) · ISI (Insomnia Severity Index)

Figures show average change from baseline across patients with that scale recorded. Lower scores mean improvement. Sample sizes (n) vary by scale. Individual results vary; these are averages, not guarantees.

THE OUTCOMES BRIEF

Want the full outcomes brief?

We’ll send the detailed, source-cited outcomes summary and can walk your team through the live dashboard.

eTMS uses FDA-cleared transcranial magnetic stimulation technology. eTMS/MeRT is not FDA-cleared for autism spectrum disorder or substance use disorder; those uses are personalized, innovative, and not a cure. Individual results vary. Outcome figures represent average change from baseline across measured patients and are not a guarantee of results. Content is for informational purposes and is not medical advice.